Close

FibroGen (FGEN) Tops Q1 EPS by 1c

Go back to FibroGen (FGEN) Tops Q1 EPS by 1c

FibroGen Reports First Quarter 2018 Financial Results

May 9, 2018 4:02 PM EDT

Pamrevlumab Data to be Presented at ATS 2018 and ASCO 2018

Roxadustat U.S. Phase 3 Clinical Studies on Track to Readout in Fourth Quarter 2018Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time

SAN FRANCISCO, May 09, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a science-based biopharmaceutical company, today reported financial results for the first quarter of 2018 and provided an update on the companys recent developments.

FibroGen and AstraZeneca are preparing to complete patient enrollment in... More